Ranexa NDA Amendment Seeks Restricted Angina Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
CV Therapeutics' complete response to FDA's October 2003 "approvable" letter is based on the ERICA trial in patients refractory to the maximum labeled dose of Pfizer's calcium channel blocker Norvasc.